Advanced search
Start date

Crystallization and polymorphism of Flubendazole and other ill-characterized drugs


Polymorphism, the ability of a substance to crystallize in more than one lattice arrangement, is currently a major concern for the pharmaceutical industry. Albeit the molecule does not change, different packing architectures can lead to significant differences in physicochemical properties that play a key role in the performance of medicines. Thus, in recent years there has been a significant increase in investments to uncover new polymorphs and other crystal forms (e.g. solvates, co-crystals) of existing active ingredients (APIs), aiming at the improvement of their safe use and therapeutic efficacy. This project falls within this scope and focuses on: (i) preparation of polymorphs, solvates, or co-crystals of APIs; (ii) their characterization in terms of structure and thermodynamic stability; (iii) their in silico evaluation in terms of biopharmaceutical performance.The main target molecule will be the antihelmintic and potential antitumor agent flubendazole, for which, to the best of our knowledge, no polymorphism studies have been reported. This represents a significant drawback for the safe use, manufacture and quality control of pharmaceutical formulations based on this active principle. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications (5)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DE ARAUJO, GABRIEL L. B.; FERREIRA, FABIO FURLAN; BERNARDES, CARLOS E. S.; SATO, JULIANA A. P.; GIL, OTAVIO M.; DE FARIA, DALVA L. A.; LOEBENBERG, RAIMAR; BYRN, STEPHEN R.; GHISLENI, DANIELA D. M.; BOU-CHACRA, NADIA A.; et al. A New Thermodynamically Favored Flubendazole/Maleic Acid Binary Crystal Form: Structure, Energetics, and in Silico PBPK Model-Based Investigation. Crystal Growth & Design, v. 18, n. 4, p. 2377-2386, . (15/05685-7, 15/26233-7)
DE ARAUJO, GABRIEL L. B.; ZELLER, MATTHIAS; SMITH, DANIEL; NIE, HAICHEN; BYRN, STEPHEN R.. Unexpected Single Crystal Growth Induced by a Wire and New Crystalline Structures of Lapatinib. Crystal Growth & Design, v. 16, n. 10, p. 6122-6130, . (15/15456-5, 15/05685-7)
ZELLER, MATTHIAS; BARROS DE ARAUJO, GABRIEL LIMA; PARKER, TREV; RAI, AMRINDER SINGH; BYRN, STEPHEN R.. A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases. ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, v. 73, n. 3, p. 417+, . (15/05685-7, 15/15456-5)
REPIN, ILIA ALEKSEEVICH; LOEBENBERG, RAIMAR; DIBELLA, JOHN; CONCEICAO, ANTONIO C. L.; MINAS DA PIEDADE, MANUEL E.; FERRAZ, HUMBERTO G.; ISSA, MICHELE G.; BOU-CHACRA, NADIA A.; ERMIDA, CATHARINE F. M.; DE ARAUJO, GABRIEL L. B.. Exploratory Study on Lercanidipine Hydrochloride Polymorphism: pH-Dependent Solubility Behavior and Simulation of its Impact on Pharmacokinetics. AAPS PHARMSCITECH, v. 22, n. 2, . (15/05685-7)

Please report errors in scientific publications list by writing to: